Markus Gude

USPTO Granted Patents = 27 (Patent Applications = 8)

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 23 (Patent Applications = 19)

Average Co-Inventor Count = 5.9

ph-index = 7

Forward Citations = 145(Granted Patents)

Location History:

Sissach, CH (2012)
Allschwil, CH (2010 - 2021)

Company Filing History:

20 out of 217

Actelion Pharmaceuticals Ltd

patents

7 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2010-2021

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11040966 - Benzimidazole-proline derivatives (2021-06-22),

2. 10329287 - Benzimidazole-proline derivatives (2019-06-25),

3. 10023560 - Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2018-07-17),

4. 9914721 - Use of benzimidazole-proline derivatives (2018-03-13),

5. 9914720 - Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists (2018-03-13),

6. 9790208 - Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2017-10-17),

7. 9732075 - Benzimidazole-proline derivatives (2017-08-15),

8. 9493446 - [object Object] (2016-11-15),

9. 9428456 - 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives (2016-08-30),

10. 9303023 - Pyrazole and imidazole derivatives useful as orexin antagonists (2016-04-05),

11. 9211279 - Proline sulfonamide derivatives as orexin receptor antagonists (2015-12-15),

12. 9000029 - Proline sulfonamide derivatives as orexin receptor antagonists (2015-04-07),

13. 8895606 - Proline sulfonamide derivatives as orexin receptor antagonists (2014-11-25),

14. 8889676 - 3-ureidoisoquinolin-8-yl derivatives (2014-11-18),

15. 8329706 - Oxazolidinone derivatives (2012-12-11),

Title: Innovations of Markus Gude: Pioneering Research in Pharmaceutical Chemistry

Introduction

Markus Gude, a prolific inventor based in Allschwil, Switzerland, holds an impressive portfolio of 27 patents. His work primarily focuses on advancements in pharmaceutical chemistry, making significant contributions to the development of new medicinal compounds.

Latest Patents

Among his notable innovations are the benzimidazole-proline derivatives. These compounds are characterized by their specific formulae, which have been meticulously detailed in the patents. The invention discusses their preparation, the creation of pharmaceutically acceptable salts, and their application as pharmaceuticals. Notably, these compounds are identified for their potential as orexin receptor antagonists, a promising area for therapeutic applications.

Career Highlights

Markus Gude has enjoyed a fruitful career, working with renowned companies such as Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His expertise in pharmaceutical research has positioned him as a respected figure within the industry, leading to numerous innovative breakthroughs that have the potential to enhance patient care.

Collaborations

Throughout his career, Markus has collaborated with talented professionals, including Christoph Boss and Thierry Sifferlen. These collaborations have not only expanded his research horizons but have also contributed to his success as an inventor.

Conclusion

In summary, Markus Gude's contributions to pharmaceutical innovation through his extensive patent portfolio highlight the importance of research and development in medicine. His recent work with benzimidazole-proline derivatives showcases a commitment to enhancing health outcomes, reinforcing his status as a leading inventor in the field.

This text is generated by artificial intelligence and may not be accurate.